Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA233-0000  |   NCT06544655

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 11
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
    1. Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
      1. Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

        Exclusion Criteria

        Exclusion Criteria Icon
        :
        • History of or with active interstitial lung disease or pulmonary fibrosis.
          1. Active, known, or suspected autoimmune disease.
            1. Serious uncontrolled medical disorders.
              1. New onset, non-catheter-associated venous thromboembolism within the past 6 months.
                Additional Information *
                • Other protocol-defined Inclusion/Exclusion criteria apply.

                  Treatment Options

                  Study Arms

                  ASSIGNED INTERVENTION

                  Study Arms

                  Experimental: Part 1A: BMS-986484 Dose Escalation

                  ASSIGNED INTERVENTION
                  • Drug: BMS-986484

                  Study Arms

                  Experimental: Part 1B: BMS-986484 + Nivolumab Dose Escalation

                  ASSIGNED INTERVENTION
                  • Drug: BMS-986484
                  • Biological: Nivolumab

                  Study Arms

                  Experimental: Part 2A: BMS-986484 Dose Expansion

                  ASSIGNED INTERVENTION
                  • Drug: BMS-986484

                  Study Arms

                  Experimental: Part 2B: BMS-986484 + Nivolumab Dose Expansion

                  ASSIGNED INTERVENTION
                  • Drug: BMS-986484
                  • Biological: Nivolumab
                  Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                  Check Your Eligibility
                  Answer some questions about Your health to see if you may match to this trial
                  Match to a Trial
                  If you are a match, click on the study to see the list of study site locations
                  Select a Study Site Location
                  Select a study site location that is convenient for you
                  Register
                  Provide your contact details for the study site to connect with you.

                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you